Intranasal TXA for Anterior Epistaxis in the Emergency Department

• Status: Suspended
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the efficacy of and patient satisfaction with the use of intranasal tranexamic acid (TXA) for anterior nosebleeds in the emergency department (ED).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mercy Health Ohio
• Treatments: Tranexamic Acid

Criteria

Inclusion criteria:

• Patients 18 years and older with anterior epistaxis

Exclusion criteria:

• Patients with inability to give consent

• Patients without a working telephone number

• Patients lacking the mental capacity to make their own decisions

• Patients with posterior epistaxis

• Epistaxis following major trauma

• Patients with known bleeding disorder like hemophilia and thrombocytopenia

• Prisoners

• Patients hemodynamically unstable

• Pregnant patients

• Patients with a known allergy to TXA

• Patients with a visibly bleeding vessel

• Those recently post-op nasal/sinus surgery (within ten days) will also be excluded